The PTEN tumor suppressor is frequently mutated in human tumors. Loss of PTEN function is associated with constitutive survival signaling through the phosphatidylinositol-3 kinase/Akt pathway. Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed constitutive Akt activation in LNCaP prostate cancer cells and enhanced apoptosis induced by a broad range of apoptotic stimuli. PTEN expression sensitized cells to death receptor-mediated apoptosis induced by tumor necrosis factor, anti-Fas antibody, and TRAIL. PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide. PTEN-mediated apoptosis was accompanied by caspase-3 and caspase-8 activation and was inhibited by a broad speci®city caspase inhibitor Z-VADfmk. Bcl-2 overexpression also blocked PTEN-mediated apoptosis. Lipid phosphatase activity of PTEN is required for apoptosis as the PTEN G129E mutant selectively de®cient in lipid phosphatase activity was unable to sensitize cells to apoptosis. PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis as coexpression of a dominant negative FADD mutant blocked PTEN-mediated apoptosis. Since in death receptor signaling, FADD mediates activation of caspase-8, which in turn cleaves BID, and since caspase-8 is activated in PTEN-mediated apoptosis, we examined BID cleavage in PTEN-mediated apoptosis. PTEN facilitated BID cleavage after treatment with low doses of staurosporine and mitoxantrone. BID cleavage was inhibited by dominant negative FADD. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.
Introduction
The PTEN tumor suppressor (also known as MMAC1) is one of the most frequently mutated genes in human malignancies and is inactivated in a wide range of tumors, including melanoma and cancers of the brain, endometrium, and prostate (Li et al., 1997a; Steck et al., 1997) . Mice with heterozygous disruption of PTEN are predisposed to develop multiple types of tumors (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998a) . The PTEN protein, through its ability to dephosphorylate the lipid second messenger phosphatidylinositol (PI) 3,4,5-phosphate, negatively regulates survival signaling mediated by the PI 3-kinase/Akt pathway (Maehama and Dixon, 1998) . Loss of PTEN in tumor cells leads to persistent activation of the serine/threonine kinase Akt (Myers et al., 1998; Stambolic et al., 1998; Wu et al., 1998) .
Two major pathways leading to apoptosis have been elucidated (Budihardjo et al., 1999) . In the mitochondrial dependent pathway, stimuli such as stress, withdrawal of survival factors, DNA damage, or chemotherapeutic agents cause release of cytochrome c from mitochondria leading to the formation of apoptosomes' consisting of cytochrome c, Apaf-1, and procaspase-9 (Li et al., 1997b) . This results in autoactivation of procaspase-9 and subsequently activation of eector caspases and a distinct apoptotic cell death program. Another pathway involves the death signal generated at the cell membrane by receptors such as tumor necrosis factor (TNF)-a receptor and Fas (Ashkenazi and Dixit, 1999) . Binding of ligands to death receptors initiates recruitment and assembly of the death-inducing signaling complex, consisting of receptor cytoplasmic domains, adaptor proteins such as TRADD (TNF receptor associated death domain) and FADD (Fas associated death domain), and procaspase-8. Activated caspase-8 may directly activate downstream eector caspases in some cells or alternately in other cell types the death signal may be ampli®ed through mitochondria by cleavage of the proapoptotic Bcl-2 family member BID, which translocates to mitochondria and induces cytochrome c release from mitochondria and thereby leads to activation of downstream caspases Luo et al., 1998) . Signaling networks initiated by growth factor and cytokine receptors regulate apopto-sis at multiple points and more re®ned understanding of how tumor suppressors such as PTEN regulate sensitivity to apoptosis may lead to more speci®c targeting of tumor cells by cancer therapeutic agents.
Prostate cancer is the second leading cause of cancerrelated mortality in American men. Molecular mechanisms underlying development and progression of prostate cancer remain incompletely understood. PTEN function is lost in a high percentage of both localized and advanced prostate cancer tumors and this is associated with constitutive Akt activation (McMenamin et al., 1999; Suzuki et al., 1998b; Wu et al., 1998) . Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. We show that PTEN expression sensitize prostate cancer cells to multiple apoptotic stimuli in a caspase-dependent manner and that lipid phosphatase activity of PTEN is required for this function and that FADD-dependent signaling is involved in this process, both in death receptormediated and drug-induced apoptosis.
Results

Adenovirus-mediated PTEN expression suppresses constitutive Akt activation
Loss of PTEN function in cancer cells leads to constitutive survival signaling through the PI 3-kinase/Akt pathway (Myers et al., 1998; Stambolic et al., 1998; Wu et al., 1998) . In order to test the hypothesis that reconstitution of PTEN expression in prostate cancer cells will restore the sensitivity to apoptotic stimuli, we used an adenovirus vector to transduce PTEN expression eciently into PTEN-null LNCaP prostate cancer cells. As previously reported, LNCaP cells expressed phosphorylated, constitutively activated Akt, but no endogenous PTEN protein . Reconstitution of PTEN expression by adenoviral transduction completely suppressed phospho-Akt without aecting the total level of Akt ( Figure  1a) . At 24 h after infection, PTEN was expressed at a level comparable to endogenous levels and at 48 h after infection, PTEN was modestly overexpressed ( Figure  1b) .
PTEN sensitizes cells to both death receptor-mediated and drug-induced apoptosis
Adenoviral PTEN expression by itself induced apoptosis and inhibited growth of LNCaP cells when assayed 4 days after infection (data not shown), in agreement with a previous report (Davies et al., 1999) . However, Ad-PTEN did not induce apoptosis in DU145 prostate cancer cells, which express functional PTEN (data not shown). We examined the eect of PTEN expression on the sensitivity to apoptotic stimuli at an early time point. At this time point, PTEN expression by itself had a minimal eect on apoptosis (Figure 2 ). Ad-GFP infected LNCaP cells were insensitive to treatment with TNF. LNCaP cells require treatment with cycloheximide for induction of apoptosis by TNF (Kulik et al., 2001 ) (also data not shown). However, Ad-PTEN markedly enhanced induction of apoptosis by TNF. Cells infected with Ad-PTEN and treated with TNF became detached and appeared nonviable (Figure 2 ). Apoptotic cell death was con®rmed in these cells by the appearance of the cell population with the hypodiploid sub-G1 DNA content and also by a DNA fragmentation ELISA assay measuring the amount of DNA-histone complexes released into the cytoplasm. A dose of TNF as low as 1 ng/ml eciently induced apoptosis in Ad-PTEN infected cells whereas TNF at a dose of up to 100 ng/ ml did not induce apoptosis in control adenovirus infected cells (Figure 3a (Thakkar et al., 2001) . PTEN also sensitized cells to apoptosis not initiated by death ligands (Figure 4 ). Ad-PTEN infected cells became sensitized to apoptosis induced by staurosporine, a broad spectrum protein kinase inhibitor widely used to induce apoptosis. Mitoxantrone is a chemotherapeutic agent structurally related to adriamycin and is commonly used for treatment of metastatic prostate cancer. Ad-PTEN infected cells were more sensitive to mitoxantrone-induced apoptosis. Similar results were obtained with another chemotherapeutic agent etoposide (data not shown). These data show that PTEN expression lowers the threshold for apoptosis induced by both death ligands and drugs.
PTEN-mediated apoptosis involves caspases-3 and -8 activation and is inhibited by caspase inhibitor
Apoptosis is generally accompanied by activation of caspases. PTEN expression and a second apoptotic stimulus such as TNF, anti-Fas antibody or staurosporine led to marked activation of the DEVDpeptide speci®c caspase 3-like activity whereas PTEN expression or the apoptotic stimulus by itself induced caspase-3 activity only minimally ( Figure 5a ). Caspase-3 activity was inhibited by treatment with a broad speci®city caspase inhibitor Z-VAD-fmk. In addition, Z-VAD-fmk eciently blocked apoptosis induced by PTEN and a second apoptotic stimulus (Figures 3 and 4). Since death receptor signaling involves caspase-8, activation of caspase-8 was examined (Figure 5b ). PTEN expression in combination with a second apoptotic stimulus such as TNF, anti-Fas antibody or staurosporine led to activation of procaspase-8 as evidenced by appearance of cleaved caspase-8 isoforms, p43 and p41, on immunoblotting. TNF and anti-Fas antibody by itself (but not staurosporine) stimulated caspase-8 activation to a minimal extent. These data show that PTEN-mediated apoptosis involves caspase activation.
Lipid phosphatase activity of PTEN is required for apoptosis PTEN can dephosphorylate both protein and lipid substrates (Maehama and Dixon, 1998; Myers et al., 1997) . Although much evidence links its tumor suppressive properties to its lipid phosphatase activity, some studies implicate lipid phosphatase-independent (Hlobilkova et al., 2000; Maier et al., 1999; Weng et al., 2001) . To assess the requirement for lipid phosphatase activity in sensitizing cells to apoptosis, we constructed an adenovirus vector expressing the PTEN G129E mutant and tested its ability to sensitize cells to apoptosis. The PTEN G129E mutant is selectively defective in lipid phosphatase activity but retains tyrosine phosphatase activity (Myers et al., 1998) . PTEN G129E, although expressed at a comparable level to wild type PTEN, was unable to suppress Akt activation (Figure 6a ). Furthermore, it was completely inactive in sensitizing LNCaP cells to apoptosis induced by TNF (Figure 6b ) as well as agonistic anti-Fas antibody and staurosporine (data not shown). These data strongly suggest that PTENmediated apoptosis is completely dependent on the lipid phosphatase activity of PTEN.
Bcl-2 blocks PTEN-mediated apoptosis
In some cell types, death receptor signaling proceeds through caspase-8 mediated cleavage of BID, which then translocates to mitochondria and induces the release of cytochrome c from mitochondria and subsequent activation of caspases Luo et al., 1998) . In these so-called type II cells, Bcl-2 overexpression blocks the release of cytochrome c and inhibits death receptor-mediated apoptosis (Scadi et al., 1998) . To determine the contribution of the mitochondrial pathway in LNCaP cells undergoing apoptosis, we examined the eect of overexpressing Bcl-2 on sensitivity to apoptosis. LNCaP-Bcl-2 cells were completely resistant to apoptosis induced by PTEN expression plus TNF, anti-Fas antibody or staurosporine (Figure 7) . Control experiments veri®ed similar levels of PTEN expression and suppression of phospho-Akt in LNCaP-Neo and LNCaP-Bcl-2 cells (data not shown). These data, in agreement with previous results (Davies et al., 1999) , suggest that PTEN-mediated apoptosis depends on the mitochondrial pathway.
PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis Upon activation by binding to ligands, death receptors such as TNF receptor and Fas recruit and activate caspase-8 through an adaptor protein FADD. Druginduced apoptosis under certain conditions is also dependent on the presence of intact FADD-dependent signaling pathways (Micheau et al., 1999; Tang et al., 1999) . To test the involvement of the FADDdependent pathway, a dominant negative mutant of FADD (DFADD) lacking the N-terminal death eector domain was introduced via adenovirus (Chinnaiyan et al., 1996) . Co-infection with Ad-DFADD eciently blocked death receptor-mediated apoptosis induced by PTEN and TNF (Figure 8 ). Ad-DFADD also blocked drug-induced apoptosis by PTEN and staurosporine as well as PTEN and mitoxantrone. Ad-DFADD also inhibited apoptosis induced by higher doses of staurosporine alone or mitoxantrone alone (data not shown and Figure 8b ). To investigate the possibility of autocrine activation by death ligands in staurosporine-induced apoptosis, neutralizing antibodies against Fas and TNF-R1 were utilized. Pretreatment of cells with a neutralizing antibody against Fas (ZB4) or TNF-R1 (H398) had no eect on staurosporine-induced apoptosis (data not shown). In addition, quantitation of mRNA levels of components The DFADD protein appears as a doublet due to phosphorylation (Chinnaiyan et al., 1996) of death receptor signaling such as Fas, Fas ligand, caspase-8, TNF-R1, TRADD, DR4, or DR5 by ribonuclease protection assays showed no dierence between control and Ad-PTEN infected cells (data not shown). These data suggest that PTEN enhances druginduced apoptosis through a ligand-independent but FADD-dependent signaling pathway.
PTEN facilitates BID cleavage and dominant negative FADD blocks BID cleavage
Death receptor signaling downstream of FADD involves recruitment and activation of caspase-8, which in turn cleaves BID. Cleaved BID subsequently activates the mitochondrial pathway by inducing the release of cytochrome c and activation of downstream caspases Luo et al., 1998) . Since we have shown that PTEN plus staurosporine induces caspase-8 activation (Figure 5b ), we hypothesized that PTEN-mediated, drug-induced apoptosis may also involve BID cleavage downstream of FADD and examined the status of BID in cells undergoing apoptosis in response to PTEN plus drug treatment. PTEN expression and treatment with a low dose of staurosporine or mitoxantrone led to BID cleavage and thereby loss of full length BID (Figure 9 ). BID cleavage and loss of full length BID did not occur with similar drug treatment in the absence of PTEN expression. Coexpression of dominant negative FADD completely blocked BID cleavage induced by PTEN plus drug treatment. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.
Discussion
We show that PTEN sensitizes LNCaP prostate cancer cells to a broad range of apoptotic stimuli. PTEN enhances apoptosis induced by three dierent death receptors as well as by drugs and chemotherapeutic agents with distinctly dierent mechanisms of action. This is consistent with the hypothesis that PTEN may target a common cellular machinery used by many stimuli to execute the apoptotic program. However, not all apoptotic stimuli tested were aected by PTEN as PTEN did not sensitize cells to hyperosmotic shock or ultraviolet irradiation (data not shown).
PTEN regulates sensitivity to apoptosis by mechanisms involving the PI 3-kinase signaling pathway as the lipid phosphatase-de®cient mutant of PTEN that retains protein phosphatase activity is unable to suppress activated Akt and is also unable to sensitize cells to apoptosis. Akt transduces antiapoptotic signals, in part, by phosphorylating and inactivating key proteins of the apoptotic machinery, such as BAD and caspase-9 (Cardone et al., 1998; Datta et al., 1997; del Peso et al., 1997) . Phosphorylated BAD is unable to heterodimerize with Bcl-2 and is no longer proapoptotic. PTEN would be expected to enhance mitochondrial signal ampli®cation downstream of the death-inducing signaling complex. The inability of PTEN to sensitize Bcl-2 overexpressing cells to apoptosis is consistent with this model, as Bcl-2 overexpression results in inhibition of cytochrome c release from the mitochondria and blocks apoptosis in cells requiring mitochondrial ampli®cation of signals downstream of the death-inducing signaling complex (Scadi et al., 1998) .
In addition to regulating the mitochondrial pathway, PTEN is likely to regulate sensitivity to apoptosis through other mechanisms. PTEN-mediated apoptosis is dependent on the adaptor protein FADD as the dominant negative FADD mutant (DFADD) blocks apoptosis initiated by PTEN plus TNF or staurosporine or mitoxantrone. Since this dominant negative FADD mutant uncouples downstream caspase activation from ligand-induced activation of death receptors, it is expected to inhibit apoptosis by PTEN plus TNF. However, the ®nding that dominant negative FADD also blocks apoptosis induced by PTEN plus staurosporine or mitoxantrone was unexpected since staurosporine and mitoxantrone have not been linked to the death receptor signaling pathway. Since neutralizing monoclonal antibodies against death receptors had no eect on staurosporine-induced apoptosis, these data raise a possibility that drug-induced apoptosis in LNCaP cells may involve a ligand-independent but FADD-dependent signaling pathway. A similar model has been postulated from work in other systems. Apoptosis induced by chemotherapeutic agents, nonsteroidal anti-in¯ammatory drugs, lipopolysaccharide and detachment from matrix can be blocked by expression of the dominant negative FADD mutant but not by neutralizing antibodies against death receptors (Choi et al., 1998; Frisch, 1999; Han et al., 2001; Micheau et al., 1999; Rytomaa et al., 1999) . Previous reports have shown that chemotherapeutic agents cisplatin and camptothecin may induce ligandindependent aggregation of death receptors and recruitment of FADD to death receptors (Micheau et Shao et al., 2001) . Alternately, FADD may operate completely independently of death receptors as there is accumulating evidence that FADD may be involved in other functions in addition to death receptor signaling. FADD-null mice are not viable and FADD may be required for proliferation of T cells (Newton et al., 1998; Yeh et al., 1998) . More work is necessary to elucidate how PTEN aects the FADDdependent apoptotic signaling pathway. However, one caveat in interpretation of experiments performed with overexpression of a dominant negative FADD mutant is that the FADD mutant may nonspeci®cally inhibit molecules other than FADD.
Death receptor-mediated apoptotic signaling proceeds through caspase-8 activation and BID cleavage downstream of FADD. Therefore, the status of caspase-8 and BID was examined in PTEN-mediated, druginduced apoptosis. PTEN expression facilitates caspase-8 activation and BID cleavage in response to low doses of staurosporine and mitoxantrone (Figures 5b and 9 ). In the absence of PTEN, these low doses of drugs do not induce apoptosis or lead to caspase-8 activation or BID cleavage. Dominant negative FADD blocks BID cleavage induced by PTEN plus drug treatment, presumably by inhibiting caspase-8 activation. Cleaved BID induces oligomerization of proapoptotic BAK or BAX molecules on the mitochondrial membrane, triggering cytochrome c release (Eskes et al., 2000; Wei et al., 2000) . A recent report shows that cells doubly de®cient in BAX and BAK are protected from apoptosis induced by cleaved BID (Wei et al., 2001) . Furthermore, these BAX, BAK-de®cient cells are resistant to apoptotic stimuli that produce mitochondrial damage, such as staurosporine and etoposide, suggesting that these agents require apoptotic signals upstream of mitochondria (Wei et al., 2001) . Our data implicating the FADD-dependent pathway that proceeds through BID cleavage in staurosporine-and mitoxantrone-induced apoptosis in the presence of PTEN is consistent with this idea. Taken together, these ®ndings suggest the existence of an apoptotic signaling pathway from FADD to caspase-8 to BID to mitochondria in drug-induced apoptosis. PTEN expression lowers the threshold for drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage downstream of FADD. These ®ndings are consistent with two recent reports demonstrating that Akt protects LNCaP cells from apoptosis by inhibiting BID cleavage (Nesterov et al., 2001; Thakkar et al., 2001) .
Another potential mechanism by which PTEN sensitizes to TNF-and chemotherapy-induced apoptosis is through inhibition of the inducible transcription factor NF-kB since NF-kB activation by TNF and chemotherapy plays a critical role in protecting cells from apoptosis (Wang et al., 1996) . NF-kB, normally sequestered in the cytoplasm in complex with IkB, translocates to the nucleus after signal-induced phosphorylation and degradation of IkB, and in the nucleus activates transcription of antiapoptotic target genes. PTEN does not appear to aect initial steps of NF-kB activation as there was no dierence in nuclear translocation or induction of DNA binding activity of NF-kB after TNF treatment between control and PTEN-expressing LNCaP cells. Instead, PTEN inhibits the transactivation potential of the p65/RelA subunit of NF-kB in the nucleus and suppresses the transcription of certain target genes of NF-kB (M Mayo et al., manuscript submitted) . This is consistent with the postulated role of Akt in activating the transcriptional function of the p65/RelA subunit of NF-kB (Madrid et al., 2000; Sizemore et al., 1999) . These ®ndings suggest that NF-kB is a downstream target of PTEN and that PTEN inhibits the antiapoptotic function of NF-kB in sensitizing cells to TNF-induced apoptosis.
The eect of PTEN on TNF-induced apoptosis may be likened to cycloheximide, an agent that has widely been used to induce sensitivity to death ligands. Cycloheximide did not aect the activation status of Akt in LNCaP cells (data not shown). Cycloheximide is postulated to act by inhibiting translation of labile antiapoptotic proteins whose expression is induced by NF-kB. However, identity of these proteins in LNCaP cells has been elusive (Nesterov et al., 2001) . It is possible that PTEN and cycloheximide may ultimately have similar eects if PTEN inhibits transcription of NF-kB target genes and cycloheximide inhibits translation of newly transcribed genes. Further experiments are necessary to elucidate the target genes regulated by PTEN in inducing sensitivity to TNF.
Loss of PTEN is frequently associated with both localized and advanced prostate cancer specimens (McMenamin et al., 1999; Suzuki et al., 1998b; Whang et al., 1998) . In mouse models, inactivation of one of PTEN alleles leads to hyperplasia and dysplasia of prostate epithelial cells, eventually resulting in prostate cancer (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998a) . These ®ndings point to loss of PTEN as one of key steps in prostate carcinogenesis. Data presented in this work show that PTEN plays a critical role in regulating the apoptotic threshold to multiple stimuli, including death ligands and chemotherapeutic agents. Therefore, reconstitution of PTEN function or inhibition of Akt represents a promising strategy for overcoming resistance of prostate cancer cells to chemotherapy-induced apoptosis.
Materials and methods
Materials and cell culture
TNF-a, staurosporine, mitoxantrone, and propidium iodide were obtained from Sigma (St Louis, MO, USA). Anti-Fas agonistic antibody IPO-4 and antagonistic antibody ZB4 were obtained from Kamiya Biomedical (Seattle, WA, USA). Anti-TNF-R1 antibody (H398) was obtained from Alexis (San Diego, CA, USA). Z-VAD-fmk was obtained from Calbiochem (San Diego, CA, USA). LNCaP cells (American Tissue Type Collection, Manassas, VA, USA) were cultured in phenol red-free RPMI medium supplemented with 10% fetal calf serum. LNCaP cells overexpressing Bcl-2, previously described (Marcelli et al., 1999; Rao et al., 1995) , were kindly provided by Dr Marco Marcello.
Construction of adenovirus
For construction of a replication-defective recombinant adenovirus, Ad-PTEN, expressing PTEN from the CMV promoter, the PTEN cDNA was subcloned into the shuttle vector pACCMVpLpA (Gomez-Foix et al., 1992) and cotransfected into 293 cells along with pJM17. The recombinant adenovirus was isolated by plaque puri®cation. Ad-GFP virus expressing enhanced green¯uorescence protein, constructed similarly, was provided by Dr Lily Wu (Department of Urology, University of California, LA, CA, USA). Another set of recombinant adenoviruses expressing the wildtype or the G129E mutant PTEN from the CMV promoter, Ad-PTEN wt and Ad-PTEN G129E, was constructed using the AdEasy system as described, after subcloning the PTEN wt and PTEN G129E fragments into the pShuttleCMV vector (He et al., 1998) . Ad-DFADD expressing the truncated dominant negative FADD protein was obtained from Dr David Brenner (Bradham et al., 1998) . Recombinant adenoviruses were puri®ed through banding in a CsCl gradient by the UNC Viral Vector Laboratory.
Adenovirus infection and apoptosis assays
Preliminary experiments with Ad-GFP showed that the adenovirus dose of multiplicity of infection (m.o.i.) of 10 can infect 99.9% of LNCaP cells (data not shown). Therefore, we used m.o.i. of 10 in all subsequent experiments. LNCaP cells were plated at a density of 5610 5 cells per well in a 6-well plate the day before infection. On day 0, cells were infected with recombinant adenovirus. On day 1, cells were treated with indicated agents. On day 2, after 24 h of treatment, both detached and adherent cells were harvested and processed for quantitation of DNA fragmentation using the Cell Death ELISA Plus kit (Roche, Indianapolis, IN, USA) according to the manufacturer's directions. For determination of DNA content by¯ow cytometry, cells were ®xed in 80% ethanol overnight and stained with propidium iodide (50 mg/ml) and analysed using FACSCalibur (Becton Dickinson).
Caspase assay
Caspase-3 like activity in cell lysates was assayed using a commercially available kit (Caspase-3 Cellular Activity Assay Kit PLUS, Biomol, Plymouth Meeting, PA, USA). Brie¯y, 25 mg of protein was incubated with a colorimetric substrate DEVD-pNA and cleavage of the substrate was monitored by measuring optical density at 405 nm.
Immunoblotting
Cell lysates were separated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose ®lter and probed with antibody as indicated. Goat anti-PTEN antibody (Santa Cruz, Santa Cruz, CA, USA) or mouse anti-PTEN monoclonal antibody (Cascade Bioscience, Winchester, MA, USA) was used to detect PTEN. Phospho-Akt antibody (Cell Signaling Technology, Beverly, MA, USA) detects Akt phosphorylated on Ser-473 whereas pan-Akt antibody (Cell Signaling Technology) detects both phosphorylated and unphosphorylated Akt. Anti-Bcl-2 monoclonal antibody (Santa Cruz), AU1 monoclonal antibody (Babco, Richmond, CA, USA), used to detect tagged DFADD, anti-BID antibody (Cell Signaling Technology) and anti-actin antibody (Sigma) were obtained commercially. Anti-caspase 8 monoclonal antibody (clone C15) (Scadi et al., 1997) was kindly provided by Peter Krammer.
